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REPLY
We appreciate Dr. Lengyel’s interest in our PRO-TEE study
regarding thrombolysis of prosthetic valve thrombosis (PVT) (1).
In this international registry, thrombus burden was found to be the
best predictor of complications in addition to a previous history of
stroke. A thrombus area of 0.8 cm2 identified a threshold beyond
which complications increased, irrespective of functional class.
Thus, thrombolysis is safest in patients with thrombi 0.8 cm2
and no previous stroke. In patients with larger thrombi, recom-
mendation of thrombolysis versus repeat surgery depends on the
relative risk of each modality in a particular patient (1).
Dr. Lengyel proposes to use thrombolysis in all patients with
PVT, irrespective of thrombus size and functional class. This is
mostly based on a series of prosthetic valves reported by Lengyel
and Vándor (2) where 43 cases underwent thrombolysis and 20
underwent surgery. Mortality rate was lower with thrombolysis (2
of 43 or 5% vs. 6 of 20 or 30%). However, patients were selected to
undergo surgery as opposed to thrombolysis if they had a left atrial
thrombus, if they presented with a stroke, or if they failed
thrombolysis. This selection most likely contributed to the higher
mortality rate of the small surgical group and to the lower mortality
of the thrombolysis group. Furthermore, it is difficult to negate the
relation of thrombus burden to complications of thrombolysis in
that study because thrombus length was measured in only 3 of the
30 cases of obstructed valves. In the “nonobstructed” valves, the
majority of which were in New York Heart Association functional
class I and II, the thrombus length was generally small. Thrombus
area was not measured. We disagree with the statement that
thrombus burden cannot be measured with transesophageal echo-
cardiography (TEE) when the valve is obstructed. Indeed, this was
feasible in the PRO-TEE study where we found that thrombus
area was a better discriminator than thrombus length in predicting
complications. Whether three-dimensional echocardiography dur-
ing TEE further refines the quantitation of thrombus burden and
the risk of thrombolysis remains to be determined.
Dr. Lengyel also relates that recent experience with thrombol-
ysis (1996 to 2003) shows a lower incidence of embolic phenomena
(4%) and death rate (2.5%) compared to earlier experience. These
complication rates are quite low compared to most reported series,
including Dr. Lengyel’s (1–3). While the exact reasons for this
difference may not be readily apparent, imaging with TEE prior to
management decision and avoidance of patients at high risk with
large thrombi are likely contributing factors. In fact, in PRO-
TEE, the use of thrombolysis irrespective of thrombus size in some
centers provided a wide range of thrombus burden and allowed the
evaluation of the relation of thrombus size to complications. The
complication rate observed in PRO-TEE (embolic rate: 14%;
death rate: 5.6%) was similar to reported series not using TEE to
guide therapy, pointing to less selection bias.
Thus, we maintain that TEE is essential in the management of
patients with suspected PVT. The PRO-TEE registry, although
retrospective, identified for the first time the threshold of a “small
clot” beyond which risk of complications increases with thrombol-
ysis. Thrombolysis has the least complications with thrombi 0.8
cm2 and no previous stroke. In these patients, thrombolysis in our
opinion should be a first-line therapy, regardless of functional
class, unless contraindications are present. With larger thrombi,
risk of complications appears to be incremental. Although throm-
bolysis is not an absolute contraindication in patients with larger
thrombi, the choice of thrombolysis versus repeat surgery in these
patients depends on the relative risk of each modality in a
particular patient and institution. These recommendations await
further validation in a prospective multicenter trial.
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Cardiologist in the Carotids
I read with interest the viewpoint by Dr. Gray (1), which reviews
the case for carotid stenting. As an emerging technology, carotid
stenting can be an important therapeutic modality for high surgical
risk patients, and has the potential for expanded applications in
additional patient groups.
What is the cardiac surgeon’s role in the development and
dissemination of carotid stents? Should one specialty alone be a
gatekeeper for the introduction and performance of new endovas-
cular procedures? Dr. Gray argues that cardiologists should be at
the forefront of the wave to deploy endoluminal stents for carotid
artery disease owing to their familiarity with complex percutaneous
interventional procedures, and their ability to manage carotid-
body–related medical issues. Cardiac and vascular surgeons are
similarly capable of performing the technically demanding skills
involved in carotid stenting, and they are also qualified to handle
the postprocedure medical sequelae. Cardiac and vascular sur-
geons, in contrast to cardiologists, are capable of managing
life-threatening and device-related surgical complications. How-
ever, catheter-based skills are absent from the curriculum of most
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cardiac surgery training programs. Hence, a majority of graduating
and practicing cardiac surgeons lack the necessary skills to rou-
tinely incorporate endovascular procedures into their practice.
Cardiac surgeons, cardiologists, interventional radiologists, and
vascular surgeons should unite to develop multispecialty endovas-
cular training programs and determine national credentialing
standards for carotid stenting. Moreover, cardiac surgeons must
take advantage of this opportunity to address the broader issue of
endovascular training within our specialty. Vascular surgery has
already incorporated endovascular experiences into their training
regimens. As a result, many graduating vascular surgery residents
possess catheter-based skills and are engaged in the practice of
“endovascular surgery.” The American Board of Thoracic Surgery
should consider adding an endovascular component to the gradu-
ating certification requirements. Cardiac surgeons can currently
obtain training in catheter-based procedures only through a
limited number of nonaccredited fellowships. If cardiac surgeons
are to be realistically involved in catheter-based procedures (and they
should), it is time that cardiac surgery training programs either: 1) add
individuals to their faculty with advanced endovascular skills; 2)
encourage existing faculty to retrain in catheter-based procedures; or
3) allow their residents to spend quality time during their residency
with clinicians who have extensive endovascular experience.
Who performs carotid stenting is a highly charged issue, and
perhaps it will be the sentinel event that can bring diverse
specialties together to create a national standard for training and
credentialing in endovascular procedures. I believe the optimal
solution will be a multidisciplinary based approach, so that
qualified physicians from a number of specialties will be able to
offer carotid stenting to their patients. Working through these
issues now will also potentially make the introduction and dissem-
ination of newer catheter-based therapies, such as percutaneous
valves and cellular therapies for heart failure, more straightforward
and less contentious.
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Dr. Wheatley’s letter appropriately raises several important issues
related to carotid stenting, and the potential operators and path-
ways to becoming expert in this emerging field. However, my
editorial (1) did not suggest cardiologists should be alone at the
forefront of the “new wave” of carotid stenting. New operators are
not assigned; rather, they declare themselves by virtue of interest,
dedication, practice type, access to patients, training, and, yes, skill
sets. It is noteworthy, however, that the significant majority of
carotid stenting performed worldwide and in this country has been
by cardiologists and that both device development and the pivotal
research owe much to that specialty (2). We would not be having
this and other debates about specialty involvement had cardiology
folded its tents under the barrage of criticism it received and had
not proven the efficacy of carotid stenting.
Inclusion of cardiac surgeons to the current potpourri of
cardiologists, vascular surgeons, radiologists, neurointerventional-
ists, neurosurgeons, and neurologists currently claiming a role in
carotid stenting is not a priori a nonstarter. However, cardiac
surgeons will be held to the same standards by most local hospital
credentialing committees. This generally means that they will need
to have all the requisite catheter-based skills (access, angioplasty,
stenting, wire manipulation, etc.) that are generally acquired by
noncardiologists by the performance of peripheral intervention.
Further, they will need the rapid exchange and 0.014-inch wire
experience necessary to move to carotid equipment. Practically
speaking, access to the carotid patients and the ability to assess
their clinical indications for carotid revascularization via interpre-
tation of the various imaging modes currently available, the
performance and interpretation of cerebral angiography, and judg-
ing the clinical appropriateness of any, and which, carotid inter-
vention (surgical or endovascular) involves new cognitive skills that
are achievable but require a dedicated effort. Finally, working on
nonanesthetized patients has been a test for several specialties
entering this field who are generally accustomed to it.
Although it appears that cardiac surgery may, in fact, be one of
the specialties most challenged when it comes to making up the
current deficits outlined above, Dr. Wheatley raises an important
point: acquiring these requisite skills will serve the surgeon well as
other technologies currently in development (percutaneous valve
therapies, heart failure devices, and so forth) emerge for patients they
are currently operating on. These skills will better position them to
take part in, rather than to lose, the care of these patients. I would
suggest those skills could be achieved without performing carotid
stenting, where the consequences of complications may be irretriev-
able even by the surgeon and are devastating for all involved.
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Advantage of Percutaneous Coronary
Intervention Over Medical Therapy
in Angina Relief and the Placebo Effect
In the Medicine, Angioplasty, or Surgery Study (MASS-II)
recently published in the Journal, Hueb et al. (1) compared the
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